Dr. Mark Scholz Discusses Treatment Issues For Advanced Prostate Cancer

At the recent 2011 Prostate Cancer Research Institute Dr. Mark Scholz discussed care issues for men with advanced metastatic prostate cancer. In his presentation he stressed the importance of closely monitoring each man’s individual, on-going response to treatment to determine its effectiveness. He made a case that without close monitoring; treatment decisions would lag behind [...]

Carboplatin – A 2nd line chemotherapy?

Carboplatin is a chemotherapy agent used for treatment of many types of cancer. Currently, it is approved by the Food & Drug Administration (FDA) for treating patients with ovarian and non-small cell lung cancer. However, some oncologists use carboplatin “off-label” for other cancers. Commonly, these “off-label” uses include testicular, stomach, and bladder cancers as well [...]

Carboplatin plus Paclitaxel Therapy after Docetaxel in Men with Metastatic Castrate Resistant Prostate Cancer

UroToday.com published a dual-center study today that confirms that carboplatin and paclitaxel (a taxane product) has an active effect on PSA when used in the treatment of men with castrate resistant prostate cancer (CRPC) after docetaxel (chemotherapy for prostate cancer). […]

Carboplatin plus Paclitaxel Chemo After Failed Docetaxel – An Alternative When There Is None

Docetaxel is the first-line chemotherapy and the only approved chemotherapy for men with metastatic castrate resistant prostate cancer (CRPC). We all know that Docetaxel will stop working, so what do you do when this happens? […]

Carboplatin-Taxane Combinations in the Management of Castration-resistant Prostate Cancer

The use of Docetaxel (chemotherapy) extends survival time in men with castration-resistant prostate cancer (CRPC). Many researchers believe that platinum compounds, particularly Carboplatin, when added to docetaxel (taxane-based chemotherapy) can further extend survival times. A study at the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Investigated the efficacy [...]